Work

An updated overall survival analysis with correction for protocol-planned crossover of the international, phase III, randomized, placebo-controlled trial of regorafenib in advanced gastrointestinal stromal tumors after failure of imatinib and sunitinib (GRID)

Year: 2015

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdv344.21

Authors: E. Fumagalli, P. Reichardt, Y. Kang, J. Blay, H. Joensuu, K.B. Schaefer, I. Kuss, C. Kappeler, G.D. Demetri

Institutions: Fondazione IRCCS Istituto Nazionale dei Tumori, Helios Hospital Berlin-Buch, Asan Medical Center, University of Ulsan, Centre Léon Bérard, Helsinki University Hospital, Bayer (Germany), Dana-Farber Cancer Institute

Language: English

Topic: Gastrointestinal Tumor Research and Treatment

Subfield: Gastroenterology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2397070718

FWCI:

Cites:

Cited by: 1

Related to: 10